Prudent Man Advisors LLC Buys Shares of 1,608 Integer Holdings Co. (NYSE:ITGR)

Prudent Man Advisors LLC purchased a new position in shares of Integer Holdings Co. (NYSE:ITGR) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 1,608 shares of the medical equipment provider’s stock, valued at approximately $209,000.

Other institutional investors have also made changes to their positions in the company. Contravisory Investment Management Inc. increased its position in Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 80 shares during the last quarter. Huntington National Bank lifted its holdings in Integer by 8,933.3% in the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 268 shares during the last quarter. Quest Partners LLC boosted its position in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares during the period. GAMMA Investing LLC grew its holdings in Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares during the last quarter. Finally, Innealta Capital LLC bought a new position in shares of Integer in the second quarter valued at approximately $110,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on ITGR shares. KeyCorp upped their price objective on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Truist Financial decreased their price target on shares of Integer from $150.00 to $147.00 and set a “buy” rating for the company in a report on Friday, October 25th. Citigroup lifted their price objective on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Bank of America increased their target price on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $140.00 price target (up from $125.00) on shares of Integer in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Integer currently has a consensus rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Stock Up 1.0 %

ITGR stock opened at $134.55 on Tuesday. Integer Holdings Co. has a twelve month low of $84.75 and a twelve month high of $140.91. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market cap of $4.51 billion, a PE ratio of 41.53, a price-to-earnings-growth ratio of 1.91 and a beta of 1.09. The business’s 50-day simple moving average is $129.20 and its 200 day simple moving average is $122.75.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million for the quarter, compared to analyst estimates of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. Integer’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.27 EPS. On average, research analysts anticipate that Integer Holdings Co. will post 5.34 earnings per share for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.